ERBB2 and neoplasm: In summary, the data presented provide evidence that it is possible to generate monocytes from BM haematopoietic CD34+ stem cells of cancer patients, which show the ability to effectively present TAA or HER-2/neu369–377 dominant peptide and to act as cytotoxic cells against tumour cells in vitro.